U.S. Stock Market Midday Update

Vor BioPharma rose 7.58%, with increased trading volume. Based on recent important news:

1. On July 11, Vor Biopharma announced the appointment of Sandy Mahatme as Chief Financial Officer and Chief Business Officer, leading to a 6.1% increase in stock price after hours.

2. On July 10, Vor Biopharma submitted an initial beneficial ownership statement, confirming Mahatme as a beneficial owner.

3. On July 9, analysts downgraded Vor Biopharma's rating to "Sell," citing expected pressure on the stock price.

Top Stocks by Industry Trading Volume

MiNK Therapeutics surged 569.86%. Based on recent important news:

1. On July 11, MiNK Therapeutics announced that its experimental cell therapy agenT-797 achieved complete remission in a patient with advanced testicular cancer, driving the stock price up by 522%.

2. On July 11, the successful case of the agenT-797 therapy was published in Oncogene, further boosting market confidence.

3. On July 11, more evidence supported the potential of iNKT cell therapy in treating solid tumors, leading to a significant increase in stock price.

AbbVie fell 1.33%, with increased trading volume. Based on recent important news:

1. On July 11, AbbVie signed a licensing agreement with Indian pharmaceutical company Glenmark, paying $700 million, which caused stock price fluctuations.

2. On July 10, analysts maintained a "Moderate Buy" rating for AbbVie but did not include it in their recommended list, affecting market confidence.

3. On July 9, increased volatility in the innovative drug sector and a low allocation ratio by institutions led to a decline in stock price.

Gilead Sciences fell 3.52%, with increased trading volume. Based on recent important news:

1. On July 9, Gilead reached an agreement with the Global Fund to accelerate the supply of the HIV prevention drug Lenacapavir to low-income countries, raising market concerns about profitless sales impacting earnings, resulting in a 3.52% drop in stock price.

2. On July 9, Gilead entered into an agreement with Kymera Therapeutics to develop a novel molecular glue degrader, with the market taking a wait-and-see approach regarding its long-term benefits.

3. On July 11, analysts noted that Gilead was not included in the best buy list, rating it as "Moderate Buy," which affected market confidence.

Top Stocks by Industry Market Capitalization

Amgen fell 1.72%, with increased trading volume. Based on recent important news:

1. On July 10, analysts believed that Amgen's stock is currently reasonably valued, with a price-to-earnings ratio below the industry average, attracting income-seeking investors, but failing to make it onto the top analysts' recommended list, leading to insufficient market confidence and a 1.72% drop in stock price

2. On July 9th, news emerged that Oregon representative Cliff Bentz purchased Amgen stock. Although the transaction amount was not large, it failed to boost market sentiment, and the stock price slightly fell by 0.11%.

3. On July 8th, market analysis pointed out that Amgen's defensive growth positioning is suitable for the current macro environment, but analysts only assigned a hold rating, failing to stimulate investor buying interest